Credit Suisse analyst Vamil Divan believes Celltrion press releases and Teva's comments still point to September approval for Fremabezumab. While the analyst would certainly prefer a cleaner story heading into the Action Date, he is comfortable enough with the company comments to maintain a cautiously optimistic view.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."